Advertising a prescription treatment: FDA vs FTC

A practice that offers a prescription treatment wants to say so: on the website, in a search ad, in a post. The questions follow quickly. Is this a prescription drug ad under FDA rules? Does the practice need the long side effect summary seen in drug company ads? Can the ad name the drug, mention a use the label does not list, or promote a compounded version? This guide sorts out which agency’s rules reach a practice’s own ads, what the law says about each kind of claim, and what Google and Meta require before the ad runs.

Related guides cover neighboring ground. Pharmacies that compound are in our compounding pharmacy marketing guide, online dispensing and controlled substances are in online pharmacy advertising rules, and clinic-specific claims are in our guides to IV therapy clinic marketing and weight loss clinic marketing. This one stays with the practice side: a clinic advertising a treatment it prescribes or administers. For injectables at med spas, see our guide to neuromodulator and injectable advertising. For the prescription eyelash drug and cosmetic lash serums, see our guide to eyelash serum advertising rules. For prescription sweating treatments and their age and body-area limits, see our guide to hyperhidrosis treatment marketing. For a prescription vitiligo cream with a boxed warning and an age limit, see our guide to vitiligo treatment advertising.

This is general information, not legal advice. Sources cited were checked on October 31, 2026: 21 USC 352(n) and 396; 21 CFR 202.1; 15 USC 45, 52 and 55; the 1971 FTC and FDA Memorandum of Understanding; the FTC Health Products Compliance Guidance (December 2022); FDA pages on telehealth promotion of compounded drugs (content current as of June 15, 2026) and on unapproved use of approved drugs (content current as of February 5, 2018); Tex. Occ. Code 101.201; 22 TAC 164.3; Google Ads healthcare and medicines, prescription drug services and restricted drug terms policies; and Meta’s Drugs and Pharmaceuticals ad standard. We found no FDA rule or guidance written for a physician practice advertising its own services as such. State law differs, so have a health care attorney in your state review your treatment pages and ads.

The short version

The FDA prescription drug ad rules in 21 USC 352(n) and 21 CFR 202.1 put the duty on the manufacturer, packer or distributor of the drug. They are the reason drug company ads carry a brief summary of side effects.
The FTC Act bars false advertisements for drugs, devices and services (15 USC 52), and a false advertisement includes one that leaves out material facts (15 USC 55(a)(1)). A practice ad for a treatment is an ad for a service and, in part, for a drug.
Under a 1971 agreement, the FDA has primary responsibility for the truth of prescription drug advertising and the FTC for other advertising of drugs, devices and services. Neither document names physician practices.
A physician may prescribe an approved drug for an unapproved use when medically appropriate, according to the FDA. Advertising that use is a separate question, and FDA rules bar a manufacturer’s ad from suggesting uses outside the approved labeling (21 CFR 202.1(e)(4)(i)(a)).
Compounded drugs are not FDA approved. The FDA has warned telehealth companies against calling them generic, the same as an approved drug, FDA approved, or clinically proven to match the approved drug.
Google lets U.S. ads and landing pages use prescription drug terms, but keyword targeting of those terms needs certification, and telemedicine providers need LegitScript certification. Meta requires LegitScript certification or Meta review, plus authorization, for ads that promote prescription drugs.
State medical boards add their own rules. Texas, for example, bars health care advertising that is false, misleading, deceptive or not readily subject to verification (Tex. Occ. Code 101.201(a)).

Who regulates what: FDA, FTC and the practice

Section 502(n) of the Food, Drug, and Cosmetic Act, codified at 21 USC 352(n), treats a prescription drug as misbranded unless the manufacturer, packer or distributor includes, in all advertisements it issues or causes to be issued for that drug, a true statement of the established name, the quantitative formula, and a brief summary of side effects, contraindications and effectiveness as FDA regulations require. FDA’s rule at 21 CFR 202.1 fills in those duties. It lists the media it reaches, including journals, magazines, newspapers, and radio, television and telephone broadcasts (21 CFR 202.1(l)(1)), and it sets the brief summary and “major statement” requirements for drug ads (21 CFR 202.1(e)).

The statute names who carries that duty: the manufacturer, packer or distributor. A practice that prescribes or administers a drug it buys is not named. Whether a practice that repackages, compounds or distributes drugs takes on any of those roles is a question for your attorney, and we found no FDA guidance that answers it for physician practices as such. Materials a manufacturer distributes through patient support programs are a separate case, discussed in our guide to specialty pharmacy and patient support program marketing.

The FTC side is broader. Section 12 of the FTC Act makes it unlawful to disseminate a false advertisement likely to induce the purchase of food, drugs, devices, services or cosmetics (15 USC 52(a)), and treats it as an unfair or deceptive act under Section 5 (15 USC 52(b), 45(a)). A false advertisement is one that is misleading in a material respect, judged by what it says or suggests and by the material facts it fails to reveal about the consequences of use (15 USC 55(a)(1)). The statute also carves out prescription drug ads covered by FDA’s regulations from those FTC sections for the matters the regulations cover (21 USC 352(n)(B)).

The two agencies divided the work in a Memorandum of Understanding signed in 1971. It says that, with the exception of prescription drugs, the FTC has primary responsibility for the truth or falsity of advertising of foods, drugs, devices and cosmetics, and that the FDA has primary responsibility for the truth or falsity of prescription drug advertising. The FTC’s Health Products Compliance Guidance (December 2022) describes the same split and says that all parties who take part directly in marketing, or who have authority to control it, have an obligation to make sure claims are truthful and supported.

No federal rule says which agency would look first at a clinic’s ad for a treatment that includes a prescription drug. We recommend writing the ad so it would pass both tests: no claim about the drug that its approved labeling does not support, and no claim about the service that you cannot back with evidence.

What a treatment ad can say about the drug

The FTC guidance says claims about the health benefits or safety of drugs and other health-related products need competent and reliable scientific evidence, and that for health benefits this generally means randomized, controlled human clinical testing. That standard applies to what a practice says about outcomes, speed and safety, whether the claim is about the drug or the service around it.

For an approved drug, the approved labeling is the natural reference. If your page describes what the drug does, who it is for, and its risks, match the labeling’s indications and warnings rather than a summary from a marketing deck. A page that lists benefits and leaves out risks material to the decision runs into the omission part of 15 USC 55(a)(1).

Prices raise their own questions, and a separate guide covers advertising cash prices. For a drug, state clearly whether a listed price includes the medication, the visit, follow-up visits and labs.

Off-label uses

The FDA explains on its patient page about unapproved uses that once it approves a drug, health care providers generally may prescribe it for an unapproved use when they judge it medically appropriate for their patient. Federal law also says nothing in the Act limits a practitioner’s authority to prescribe or administer a legally marketed device for any condition within a legitimate practitioner-patient relationship, while keeping the existing prohibition on promoting unapproved uses of devices (21 USC 396).

Prescribing is not the same as advertising. FDA’s rule bars a manufacturer’s prescription drug ad from recommending or suggesting any use not in the approved labeling (21 CFR 202.1(e)(4)(i)(a)). We found no FDA rule that applies that sentence to a physician practice’s service ads as such. The FTC test still applies, and an ad that presents an off-label use as established, approved or proven, without evidence of that strength, risks being misleading under 15 USC 55(a)(1). We recommend that a practice that offers an off-label use say plainly that the use is not FDA approved for that purpose and describe the evidence honestly, and that it have counsel review the page before the ad runs.

Compounded versions

The FDA’s page for telehealth companies says compounded drugs are not reviewed by the agency for safety, effectiveness or quality before marketing, and that the FDA has issued warning letters about false or misleading claims. It lists claims to avoid: branding that falsely or misleadingly implies the company is the compounder; describing a compounded drug as a generic version of, or the same as, an FDA-approved drug; claiming a compounded drug is FDA approved or has been evaluated for safety and effectiveness; describing it as clinically proven to produce the same result as the approved drug; and claiming it comes from an FDA-approved or FDA-licensed pharmacy or outsourcing facility, since the FDA does not approve or license facilities.

The page is addressed to telehealth companies, but each listed claim is about the drug, and a practice that advertises a compounded treatment can make the same claims. We recommend using that list as a check on each compounded treatment page. Who may compound and for whom is a separate set of rules covered in our compounding pharmacy guide.

Google and Meta requirements

Google’s restricted drug terms policy, read on October 31, 2026, says campaigns targeting the United States, Canada or New Zealand may use prescription drug terms for promotional purposes in accordance with local laws, and that certification is not needed to use the terms in ads and landing pages but is needed to keyword-target them. Certification is also required for certain business types, including online pharmacies, telemedicine providers and pharmaceutical manufacturers. Google’s healthcare and medicines policy says that in the United States, telemedicine providers must be accredited through LegitScript’s Healthcare Merchant Certification Program and certified with Google.

Google’s prescription drug services policy says Google decides whether an advertiser promotes online prescribing, dispensing or sale of prescription drugs from the content of its ads, site or app and the services it offers, and that it errs on the side of caution for landing pages that appear to facilitate online prescribing. A clinic with an online booking page for a prescription treatment should expect that review.

Meta’s Drugs and Pharmaceuticals ad standard, read on October 31, 2026 through the Internet Archive, says ads that promote prescription drugs may run only if the advertiser is certified by LegitScript or has gone through Meta’s internal review, has completed Meta’s onboarding for prescription drugs, targets only the United States, Canada or New Zealand where it is certified, and targets only people 18 or older. It says online pharmacies and telehealth providers must be certified with LegitScript, and that ads that educate about prescription drugs or promote telehealth services generally do not need written authorization.

State medical board rules

State rules sit on top of the federal ones and reach the practitioner’s license. In Texas, health care advertising may not be false, misleading, deceptive or not readily subject to verification, and that includes a material misrepresentation of fact, an omission that makes the ad misleading, and a representation likely to create an unjustified expectation about results (Tex. Occ. Code 101.201(a), (b)(1), (b)(2)). The Texas Medical Board’s rule adds items such as claiming a unique or exclusive skill without substantiation and failing to disclose a paid presentation (22 TAC 164.3(b)). Read your own state’s medical practice act and board advertising rule; our physician advertising rules guide is a starting point.

Questions to ask before the ad runs

Is the drug approved for the use the ad describes, or is it an off-label use or a compounded preparation?
Does each benefit claim match the approved labeling, and do we have evidence for any claim about outcomes or speed?
Does the page state the risks a patient needs to make the decision, not only the benefits?
Does any wording suggest a compounded drug is generic, the same as, or as proven as an approved drug?
Do we repackage, compound or distribute drugs, and has counsel told us whether that changes our duties under 21 USC 352(n)?
Do our ad accounts have the certifications Google and Meta require for what we promote and the keywords we target?
Has our state board’s advertising rule been read against the page?

Use and avoid

Use: “Treatment includes a prescription medication if your clinician decides it is appropriate after an evaluation.”
Avoid: “Get your prescription today, no questions asked.” A prescription depends on the evaluation, and the ad should not promise one.
Use: “This medication is compounded by a licensed pharmacy. Compounded drugs are not FDA approved.”
Avoid: “The same medicine as the brand, for less.” The FDA lists this kind of claim as false or misleading for compounded drugs.
Use: “Your clinician will explain the known risks and side effects before you start.”
Avoid: A benefits list with no mention of risks on a page meant to sell the treatment.
Use: A plain statement that a use is not FDA approved for that purpose, when it is not.
Avoid: “Clinically proven” or “FDA approved” for an off-label use or a compounded drug.

An illustration

This example is invented. [Practice name] offers a prescription treatment and wants to run search ads to a treatment page. The first draft headline says the treatment is “the same as the brand-name drug at half the price”, the page lists benefits only, and the campaign bids on the drug’s name.

The reviewer starts with the drug. The practice uses a compounded version, so the headline repeats a claim the FDA lists as misleading. The new page says the medication is compounded, that compounded drugs are not FDA approved, what the visit includes, and that the clinician decides after an evaluation. It adds the known risks next to the benefits, drawn from the labeling of the approved drug and reviewed by the medical director.

Then the account. Keyword-targeting the drug’s name needs Google certification, which the practice does not have, so the campaign targets service terms instead while counsel and the office manager look at whether a certification applies. The state board rule is read against the final page before launch.

Checklist

List each treatment page and ad that mentions a prescription drug, and note whether the drug is approved for that use, used off-label or compounded.
Match benefit and risk wording to the approved labeling, and keep the evidence for any outcome claim in a file.
Remove generic, same-as, FDA approved and clinically proven claims for compounded drugs.
State clearly what a listed price includes.
Check Google and Meta certification needs for the services, terms and keywords you use.
Ask counsel whether any repackaging, compounding or distribution changes your federal duties.
Read the state medical board advertising rule against each page, and repeat the review when a treatment or drug changes.

How we help

We build websites, local and organic search, Google Ads and lead generation and an AI front desk for independent practices. For prescription treatments, that means treatment pages written from the labeling and reviewed by your clinicians, ads that avoid the claims the FDA has flagged, and campaigns set up within each platform’s certification rules. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We are not a healthcare provider and we do not give legal or medical advice. For the wider rules, see our healthcare marketing rules guide.

Can a doctor advertise prescription drugs?

A practice can advertise a treatment it provides, including one that involves a prescription drug. The FDA’s prescription drug ad rules in 21 USC 352(n) and 21 CFR 202.1 place their duties on the drug’s manufacturer, packer or distributor. The FTC Act bars false or misleading ads for drugs and services (15 USC 52, 55), and state medical board rules apply as well.

Does a practice ad need the brief summary of side effects?

The brief summary requirement in 21 USC 352(n) applies to ads issued by the manufacturer, packer or distributor. We found no FDA rule extending it to a physician practice’s service ads as such. Leaving out risks that matter to the decision can still make an ad misleading under 15 USC 55(a)(1), so state the known risks.

Can we advertise an off-label use?

The FDA says providers generally may prescribe an approved drug for an unapproved use when medically appropriate. FDA rules bar a manufacturer’s ad from suggesting uses outside the labeling (21 CFR 202.1(e)(4)(i)(a)). A practice ad for an off-label use must not be misleading, so say the use is not FDA approved and describe the evidence honestly, and have counsel review it.

Can we call a compounded drug a generic?

No. The FDA’s page for telehealth companies says a compounded drug is not FDA approved, while generic drugs are approved before marketing, and it lists calling a compounded drug a generic version of, or the same as, an approved drug as a false or misleading claim.

Do we need certification to run Google or Meta ads for a prescription treatment?

On Google, U.S. ads and landing pages may use prescription drug terms without certification, but keyword targeting those terms needs certification, and telemedicine providers need LegitScript accreditation and Google certification. On Meta, ads that promote prescription drugs need LegitScript certification or Meta review, plus authorization, and may target only people 18 or older.

Advertising a prescription treatment: what the FDA and FTC rules mean for a practice